Needle Moving Activity Spotted in Alcobra Ltd. (NASDAQ:ADHD)

Cornelia Mascio
Ottobre 13, 2017

Session activity on Alcobra Ltd.(NASDAQ:ADHD) shares bumps the stock on today's most active list. Narrowing in, the stock is at a distance of -8.37% from the 50 day high and 22.94% off of the 50 day low.Covering sell-side analysts have recently weighed in on shares of Alcobra Ltd. (NASDAQ:ADHD). Citadel Advisors LLC now owns 100,114 shares of the biotechnology company's stock valued at $114,000 after acquiring an additional 101,514 shares during the period. With short interest at 876,447 and short average daily volume at 80,645, the short-interest ratio is 11.0 and the percentage of shorted shares was 0.03% on September 15. The correct version of this piece can be viewed at As of quarter end Goldman Sachs Group Inc had disposed of a total of 17,791 shares trimming its position 39.5%. For the quarter, shares have been noted at 91.52%.

Panagora Asset Management Inc grew its ownership by buying 265,202 shares an increase of 142.1% from 03/31/2017 to 06/30/2017. The value of the company's investment in Alcobra Ltd. - Ordinary Shares decreased from $51,000 to $30,000 decreasing 41.2% quarter over quarter. As of quarter end Two Sigma Investments, Lp had bought 700 shares growing its holdings by 3.2%. The value of the investment in Alcobra Ltd. - Ordinary Shares went from $401,000 to $337,000 a change of $64,000 quarter to quarter.

Shares of Alcobra (ADHD) opened at 1.12 on Wednesday. That puts total institutional holdings at 8,838,922 shares, according to SEC filings.

On October 9 the stock rating was upgraded from "Hold" to "Speculative Buy" with a current price target of $2.00 by WBB Securities.

In the market the company is trading unchanged by 0.00% percent from yesterday's close. The company's 50-day moving average is $1.06 and its 200 day moving average is $1.11. The 50 day moving average went up by +3.53% and the 200 day average moved down $-0.02.

In the latest earnings report the EPS was $-0.76 and is expected to be $-0.50 for the current year with 27,562,000 shares now outstanding. Next quarter's EPS is forecasted to be $-0.07 with next year's EPS anticipated to be $-0.53.

Alcobra Ltd is a development-stage biopharmaceutical company. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical trial in adolescents and adults with Fragile X Syndrome. Alcobra headquartered in Tel Aviv, Israel.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE